Log In

 
Company : Frost & Sullivan 
Monday, March 26, 2007 4:06PM IST (10:36AM GMT)
 
Increased Funding and Developing Regulatory Framework Provide Impetus to Stem Cell Therapeutics Market
Mumbai, Maharashtra, India

Stem cell research is among the most exciting frontiers of medical science as it promises to cure a number of debilitating disorders. Not surprisingly then, several start-ups with innovative research programmes covering a wide range of therapeutic disorders have already been established. And, despite several regulatory, social, ethical, scientific and financial hurdles, funding increases and developing regulatory frameworks are supporting the expansion of the global stem cell therapeutics market.

Stem cells are being investigated for the treatment of several disorders, such as Parkinson's disease and cancer, which currently have no cure. Adult stem cell therapies have been around in the market for three decades now but their application has been limited. On the other hand, embryonic stem cells are widely regarded as the proverbial holy grail of medical science.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the World Stem Cell Therapeutics Markets (M067- 52) then send an e-mail to Shwetha Thomas / Nimisha Iyer, Corporate Communications, at sthomas@frost.com /niyer@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"An ageing population and the lack of effective therapies for numerous disorders, apart from an increase in R&D funding will be the main drivers in the world stem cell therapeutics market," opines Frost & Sullivan (http://healthcare.frost.com) Research Analyst Sumanth Kambhammettu in a recent study on World Stem Cell Therapeutics Markets. "An improving regulatory environment in some countries coupled with newer applications will further boost market prospects." Finally, ongoing efforts to boost government funding for stem cell research by certain states in the US (such as California) and other countries in Europe and Asia will contribute to market growth."

However, a multitude of scientific, ethical, social and financial challenges continue to beset the commercialisation of stem cells. Currently, regulatory frameworks in most countries are at an evolutionary stage, and market participants may find it difficult to prove the benefits of stem cell therapies over existing drugs and secure reimbursement. In addition, human clinical trials of stem cell therapies may also pose a problem.

"Embryonic stem cell research has been mired in controversy with opposition from several ethical and social quarters besides which the science surrounding embryonic stem cells is itself in a very nascent stage," says Mr. Kambhammettu. "In addition, owing to the high cost of development, these therapies are expected to be very expensive, and procuring reimbursement could be an uphill task."

To support rapid market development and improve their chances of success in a high-risk market, participants need to focus on developing stronger proof-of-principle models. Strategic alliances with hospitals and medical centres of excellence will also provide synergistic benefits to both parties.

World Stem Cell Therapeutics Markets is part of the Pharmaceutical & Biotechnology Subscription, which also includes research in the following markets: European Central Nervous System (CNS) Therapeutics Markets, European Antidepressant Markets and European Cancer Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

World Stem Cell Therapeutics Markets
M067- 52

 
For News Release background on Frost & Sullivan click here
 
Media Contact Details
Nimisha Iyer, Corporate Communications - South Asia & Middle East, Frost & Sullivan, +91 (022) 4001 3400, niyer@frost.com
 
 
Submit your press release
More News from Frost & Sullivan

19/06/2017 5:32PM Image

Tata Communications Receives Accolades for its Five Awards at Frost & Sullivan's 2017 India Digital Transformation Awards

Tata Communications a leading global provider of network, cloud, mobility, security and collaboration services received top honors at the 2017 Frost & Sullivan India Digital Transformation Awards, with four awards in ...

19/06/2017 4:50PM Image

LatentView Wins Frost & Sullivan's "Analytics Solutions Provider of the Year" Award at the 2017 India Digital Transformation Awards

LatentView Analytics, one of the fastest growing data analytics firms globally, was named ‘Analytics Solutions Provider of the Year’ at the 2017 Frost & Sullivan India Digital Transformation Awards held at Mumbai.

19/06/2017 11:19AM Image

Top Establishments and Breakthrough Best Practices across Indian ICT Industry Honoured at Frost & Sullivan's 2017 India Digital Transformation Awards

For the 15th consecutive year, Frost & Sullivan hosted its "2017 India Digital Transformation Awards", lauding the best from the Indian ICT sector. Thirty-one awards were given away at the banquet, under four major ...

Similar News

29/06/2017 12:13PM

ARQ Midcap Stocks Gives its Investors' 42.66 Percentage Return on Investments

ARQ Midcap stocks outperform yet again giving 42.66% return on investments and enabling an agile, efficient and profitable ecosystem for its consumer investor.

No Image

28/06/2017 8:11PM

Locals Now Form over 50 Percent of Wipro's Workforce in the U.S.

Wipro Limited today announced that locals now form over 50% of its U.S. workforce.